Literature DB >> 16353934

Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Valeria Alcon1, Maria Baca-Estrada, Marco Vega-Lopez, Philip Willson, Lorne A Babiuk, Praveen Kumar, Rolf Hecker, Marianna Foldvari.   

Abstract

The ineffectiveness of simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies of strategies for appropriate delivery systems and adjuvants. Biphasic lipid vesicles are formulations suitable for the delivery of proteins, peptides, and oligo/polynucleotides. The purpose of these studies was to investigate the ability of biphasic lipid vesicles (as vaccine-targeting adjuvants) containing a bacterial antigen and unmethylated oligonucleotides containing CGdinucleotides - CpG motifs (CpG ODNs) to induce systemic and mucosal immune responses in pigs. Results showed that while the protein, either alone or with CpG ODNs, did not induce mucosal immune responses, administration of antigen and CpG ODNs in biphasic lipid vesicles resulted in induction of both systemic and local antibody responses after immunization using a combined mucosal/systemic approach.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16353934      PMCID: PMC2751259          DOI: 10.1208/aapsj070357

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  30 in total

1.  Mucosal immunogenicity and adjuvanticity of cholera toxin in swine.

Authors:  D L Foss; M P Murtaugh
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

2.  Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers.

Authors:  Alejandra V E Capozzo; Lilian Cuberos; Myron M Levine; Marcela F Pasetti
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

3.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.

Authors:  B R Murphy; D L Nelson; P F Wright; E L Tierney; M A Phelan; R M Chanock
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

4.  Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.

Authors:  X S Liu; I Abdul-Jabbar; Y M Qi; I H Frazer; J Zhou
Journal:  Virology       Date:  1998-12-05       Impact factor: 3.616

Review 5.  Mucosal responses to parenteral and mucosal vaccines.

Authors:  D Kaul; P L Ogra
Journal:  Dev Biol Stand       Date:  1998

6.  Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1.

Authors:  G F Gerlach; C Anderson; S Klashinsky; A Rossi-Campos; A A Potter; P J Willson
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

7.  Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.

Authors:  G M Glenn; T Scharton-Kersten; R Vassell; C P Mallett; T L Hale; C R Alving
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

Review 8.  Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.

Authors:  N A Williams; T R Hirst; T O Nashar
Journal:  Immunol Today       Date:  1999-02

Review 9.  The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins.

Authors:  D P Snider
Journal:  Crit Rev Immunol       Date:  1995       Impact factor: 2.214

10.  Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.

Authors:  I Takahashi; M Marinaro; H Kiyono; R J Jackson; I Nakagawa; K Fujihashi; S Hamada; J D Clements; K L Bost; J R McGhee
Journal:  J Infect Dis       Date:  1996-03       Impact factor: 5.226

View more
  1 in total

1.  Cochleates derived from Vibrio cholerae O1 proteoliposomes: the impact of structure transformation on mucosal immunisation.

Authors:  Reinaldo Acevedo; Oliver Pérez; Caridad Zayas; José L Pérez; Adriana Callicó; Bárbara Cedré; Luis García; David Mckee; Alexander B Mullen; Valerie A Ferro
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.